MAIA Biotechnology EBIT

As of the most recent data (March 2026), MAIA shows a EBIT of $-25M. That compares with $-17M in the prior-year period — down 49.0% year over year. That is above the sector sector average of $-63M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MAIA's EBIT is now $-25M (was $-17M) — a 49.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether MAIA Biotechnology is outperforming or lagging.

The its sector sector average EBIT is about $-63M. MAIA Biotechnology is at $-25M, which is higher that average. That is roughly 59.5% above the sector mean. Use the comparison chart on this page to see how MAIA stacks up against individual peers as well.

Tracking MAIA's ebit over time shows whether MAIA Biotechnology is scaling, shrinking, or reshaping that part of the business. The current reading is $-25M That compares with $-17M in the prior-year period — down 49.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has MAIA Biotechnology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-25M) with ownership activity and broader fundamentals.